Combination gene therapy using VEGF-shRNA and fusion suicide gene yCDglyTK inhibits gastric carcinoma growth

Experimental and Molecular Pathology

Volumn 91, Issue 3, 2011, Pages 745-752

  Liu, Ting ^a   Ye, Ling ^a   He, Yongzheng ^c   Chen, Xuanmin ^a   Peng, Jie ^a   Zhang, Xiaomei ^a   Yi, Hong ^b   Peng, Fang ^b   Leng, Aimin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination gene therapy; RNA interference; Suicide gene; VEGF

Indexed keywords

CALCIUM PHOSPHATE; CYTOSINE DEAMINASE; CYTOSINE DEAMINASE THYMIDINE KINASE FUSION PROTEIN; FLUOROURACIL; HYBRID PROTEIN; NANOPARTICLE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; HYBRID GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE THERAPY; ONCOGENE; STABLE EXPRESSION; STOMACH CARCINOMA; SUICIDE GENE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE FUSION; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053636070     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.07.007     Document Type: Article

References (40)

1. Alexander H.R., Kelsen D.G., Tepper J.C. Cancer of the stomach. Cancer Principles and Practices of Ontology 1997, 1021-1054. Lippincott Raven, Philadelphia. 5th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
2. Breaux J.R., Bringaze W., Chappuis C., Cohn I. Adenocareinoma of the stomach: a review of 35years and 1710 cases. World J. Surg. 1990, 14:580-586.
3. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
4. Chen Y., Stamatoyannopiulos G., Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003, 63:4801-4804.
5. David K., Charles A.V., Gilbert B., Beatrice M. A phase I/II study of HSV-TK gene therapy for recurrent glioblastoma. Hum. Gene Ther. 1998, 9:2595-2604.
6. Detwiller K.Y., Fernando N.T., Segal N.H., Ryeom S.W., D'Amore P.A., Yoon S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 2005, 65:5881-5889.
7. Ellis L.M., Takahashi Y., Fenoglio C.J., Cleary K.R., Bucana C.D., Evans D.B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 1998, 34:337-340.
8. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
10. Gabrilovich D.J., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
11. Gong W., Wang L., Yao J.C., Ajani J.A., Wei D., Aldape K.D., Xie K., Sawaya R., Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin. Cancer Res. 2005, 11:1386-1393.
12. Guan H., Zhou Z.C., Wang H., Jia S.F., Liu W., Kleinerman E.S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 2005, 11:2662-2669.
13. Guiying Z., Ting L., Yongheng C., Chen Y., Xu M., Peng J., Yu S., Yuan J., Zhang X. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin. Cancer Res. 2009, 15(1):201-207.
14. Hwang Kyung-Sun, Cho Won-Kyung, Yoo Jinsang, et al. Adenovirus mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 2005, 5:51.
15. Matsukura N., Ohgaki H. Stomach Cancer 2003, 194-197. World Health Organization, World Cancer Rep IARC Press, Lyon, France. B.W. Stewart, P. Kleihues (Eds.).
16. Matsukura S., Jones P.A., Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 2003, 31:e77.
17. Miyagi T., Koshida K., Hori O., Konaka H., Katoh H., Kitagawa Y., Mizokami A., Egawa M., Ogawa S., Hamada H., Namiki M. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J. Gene Med. 2003, 5(30):37.
18. Moriuchi S., Wolfe D., Tamura M. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 2002, 9:584-591.
19. Moriuchi S., Glorioso J.C., Maruno M., Izumoto S., Wolfe D., Huang S., Cohen J.B., Yoshimine T. Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediumted codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther. 2005, 12:487-496.
20. Muthu Madaswamy S., Sanjay Singh Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 2009, 4:105-118.
21. Niu G., Anderson R.D., Madsen M.T., Graham M.M., Oberley L.W., Domann F.E. Dual-expressing adenoviral vectors encoding the sodium iodide symporter for use in noninvasive radiological imaging of therapeutic gene transfer. Nucl. Med. Biol. 2006, 33:391-398.
22. Nykanen A., Haley B., Zamore P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001, 107:309-321.
23. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., Watanabe Y., Sasaki T. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res. 1996, 2:1411-1416.
24. Park S.Y., Lee W., Lee J., Kim I.S. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 2008, 261:205-214.
25. Qiu Z.H., Wu C.T., Lao M.F., Pan L.Z., Li Y.M. Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes. Cancer Lett. 2002, 182(2):147-154.
26. RAINOV N.G. A phase III clinical evaluation of Herpes Simplex Virus Type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000, 11:2389-2401.
27. Ray P., Bauer E., Iyer M., Barrio J.R., Satyamurthy N., Phelps M.E., Herschman H.R., Gambhir S.S. Monitoring gene therapy with reporter gene imaging. Semin. Nucl. Med. 2001, 31:312-320.
28. Rogulski K.R., Kim J.H., Kim S.H., Freytag S.O. Glioma cells transduced with an Escherichia coli CD/HSV1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 1997, 8:73-85.
29. Shand N., Weber F., Mariani L. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex t hymidine kinase gene followed by ganciclovir. Hum. Gene Ther. 1999, 10:2325-2335.
30. Shaochuang W., Hui L., Lifeng R., Pan Y., Zhang Y. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia 2008, 10:399-407.
31. Suzuki K., Hayashi N., Miyamoto Y., Yamamoto M., Ohkawa K., Ito Y., Sasaki Y., Yamaguchi Y., Nakase H., Noda K., Enomoto N., Arai K., Yamada Y., Yoshihara H., Tujimura T., Kawano K., Yoshikawa K., Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996, 56:3004-3009.
32. Ting L., Aifa T., Guiying Z., Chen Y., Zhang J., Peng S., Cai Z. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother. Radiopharm. 2005, 20:141-149.
33. Ting L., Guiying Z., Yongheng C., Yuxiang C., Xionghao L., Jie P., Meihua X., Jianwei Y. Inhibition of gastric carcinoma growth mediumted by nanoparticles delivered tissue specific expression of yCDglyTK genes. Cancer BioTher. 2006, 5:1683-1690.
34. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 2002, 20:446-448.
35. Volm M., Koomägi R., Mattern J., Stammler G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer. Res. 1997, 17:99-103.
36. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324:1-8.
37. Xie Yunjie, Gilbert Jeff D., Kim Jae Ho Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene theraoies concomitant with p53 gene therapy. Clin. Cancer Res. 1999, 5:4224-4232.
38. Yan G.M., Irwin R.P., Lin S.Z., Weller M., Wood K.A., Paul S.M. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons. J. Pharmacol. Exp. Ther. 1995, 274:983-990.
39. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56:2013-2016.
40. Yu J.Y., DeRuiter L., Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA 2002, 99:6047-6052.